Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
In the last decade, clinical studies with bevacizumab (Avastin) in various tumors have shown encouraging results in terms of efficacy/safety. However there is no data generated in Greek population with regards to safety and efficacy of bevacizumab in front line Ovarian Cancer. Two prior global phase III randomized trials showed that the addition of concurrent bevacizumab to standard chemotherapy and maintenance bevacizumab significantly increased the PFS in patients with advanced ovarian cancer It would be relevant to document the real life clinical data of bevacizumab in combination with chemotherapy (paclitaxel/carboplatin) in Front Line Ovarian Cancer as prescribed by the medical oncologists in Greece.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
Age ≥18 years
Histologically confirmed advanced stage III (suboptimally debulked \>1cm of residual disease) or stage IV ovarian cancer fallopian tube carcinoma or primary peritoneal cancer following surgical debulking with the aim of maximal surgical cytoreduction
One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm with conventional techniques) according to RECIST criteria
ECOG performance status ≤2
Adequate haematological, renal and hepatic function
Urine protein \<2+ (dipstick)
Life expectancy of \>12 weeks
You may not be if
Previous front line treatment for ovarina cancer
Previous radiotherapy to target lesions
Patients with brain metastases and/or cancerous meningitis
Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma
Patients participating in interventional clinical trial
Clareo Health | Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer
